The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Recruiting · NCT04372615 · Registry updated 2025-07-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis | Disease Attributes, Neuroinflammatory Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, autoimmune disease, autoimmune disorder of the nervous system, autoimmune encephalitis, brain disorder, central nervous system disorder, encephalitis, immune system disorder, nervous system disorder | Recruiting | Phase 2 | 2025-07-01 | NCT04372615 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Utah | 319 |
39 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.